[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ecg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ecg":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100612471","left-bundle-branch-area-pacing-lbbap-monitoring-assistant-evaluation-of-portable-ecg-solution-100612471",false,"NCT07254013","Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of Portable ECG Solution","LBBOT","Inclusion Criteria:\n\n* Subject with indication for LBBAP using an Electrophysiology ECG monitoring system (EP System) as part of pacemaker or CRT-P or CRT-D implant procedure (de novo implant, device revision or upgrade including LOT-CRT)\n* Subject signed and dated the ICF\n\nExclusion Criteria:\n\n* Incapacitated subject or under guardianship\n* inability to understand the purpose of the study\n* Minor subjects\n* Non menopausal women\n* Patients implanted with other electrically active non cardiac devices.",true,"ALL","18 Years",{"count":20,"type":21},55,"ESTIMATED","INTERVENTIONAL",[24],"NA","To evaluate the capability to monitor LBB success criteria with the use of a Smart ECG system (ECG monitor, 12 leads ECG cable, ECG viewer software ) during a cardiac device implantation involving the placement of a pacing lead in interventricular septum area",[27,28,29,30],"Bradycardia","Left Bundle Branch Area Pacing","Cardiac Resynchronisation Therapy (CRT)","ECG",[32],"LBBAP ECG MONITORING ASSISTANT","RECRUITING","2025-11-27",{"date":36,"type":37},"2025-12-05","ACTUAL",{"date":39,"type":37},"2025-11-14",{"date":41,"type":21},"2026-03-31",{"name":43,"class":44},"MicroPort CRM","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100605048","identifying-electrocardiographic-markers-to-determine-eligibility-for-the-implantation-of-a-subcutaneous-defibrillator-100605048","NCT07157449","Identifying Electrocardiographic Markers to Determine Eligibility for the Implantation of a Subcutaneous Defibrillator.","Identifying Electrocardiographic Markers on a Standard 12-lead ECG to Determine Which Patients Are Eligible for the Implantation of a Subcutaneous Defibrillator.","Screen-ICD","Inclusion Criteria :\n\n* Patient undergoing cardiology consultation, whatever the pathology\n* Patient over 18 years of age\n* Patient having been informed and having given their oral non-opposition\n* Patient and relatives affiliated to a social security scheme\n\nExclusion Criteria :\n\n* Patients receiving cardiac stimulation\n* Patient taking part in a therapeutic trial which may interfere with the results of the research\n* Patients under guardianship.",{"count":54,"type":21},1000,"OBSERVATIONAL","The S-ICD defibrillator developed by Boston Scientific Inc. is a fully subcutaneous automatic defibrillation system that prevents and treats sudden cardiac arrest. The subcutaneous system offers the advantage of avoiding the risks associated with transvenous access, limiting serious infections and lead failures. The detection system is based on the identification of rapid ventricular arrhythmias using one of three bipolar vectors defined by the subcutaneous lead (distal and median electrode) and the generator. However, before implanting the device in a patient, it is essential to carry out a screening procedure to ensure that the patient's QRS signal amplitude is sufficient to be detected by the S-ICD. This screening procedure is carried out by recording a specific three-lead electrocardiogram (ECG), which represents the three bipolar vectors of the S-ICD. The aim of this research is to show that the recording of a standard 12-lead ECG can be sufficient to predict the eligibility of patients for S-ICD implantation. More specifically, it aims to identify electrocardiographic markers on a standard 12D-ECG that can be used to determine which patients may benefit from implantation of a subcutaneous defibrillator, thereby eliminating the need for a 3-lead screening ECG. The developments that will be carried out will be based on the development of signal analysis algorithms and decision support using artificial intelligence.",[58,30],"Defibrillator","NOT_YET_RECRUITING","2025-09-08",{"date":62,"type":37},"2025-09-15",{"date":64,"type":21},"2025-10-01",{"date":66,"type":21},"2027-06-01",{"name":68,"class":69},"Nantes University Hospital","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":70},"100599384","ai-ecg-accessory-pathway-localisation-study-100599384","NCT07083791","AI-ECG Accessory Pathway Localisation Study","AAPLS","Inclusion Criteria:\n\n* Referred for EPS procedure as part of their clinical care, with a finding of pre-excitation on their ECG\n* Manifest pre-excitation on their ECG any time prior to their procedure\n* Able to give consent\n* Minimum age 13 years old\n* Maximum age 100 years old\n\nExclusion Criteria:\n\n* Unable to give consent\n* Adults \\> 100 years old\n* Children \\\u003C 13 years old\n* Patients with known location of their accessory pathway from a previous EP study","13 Years","100 Years",{"count":81,"type":21},100,"This study seeks to validate the real-world accuracy of an AI-based algorithm for identifying the location of an accessory pathway from the 12-lead electrocardiogram",[84,85,30],"Accessory Pathway","Artifical Intelligence",[87,88,30,89,90],"AI-ECG","AI","Accessory pathway","Accessory pathway localisation","2025-07-21",{"date":93,"type":37},"2025-07-24",{"date":95,"type":21},"2025-08-01",{"date":97,"type":21},"2027-03-01",{"name":99,"class":69},"Imperial College London",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100562397","hybrid-score-to-predict-otva-soo-in-patients-with-wide-basal-qrs-100562397","NCT06602635","Hybrid Score to Predict OTVA-SOO in Patients with Wide Basal QRS","A Hybrid Score to Predict the Origin of Outflow Tract Ventricular Arrhythmias in Patients with Intraventricular Conduction Disorders or Paced Rhythm","Inclusion Criteria:\n\n* ventricular arrhythmia with a morphology indicating an outflow tract origin and a wide basal QRS complex\n* a QRS width greater than 110 ms was considered wide\n* willing and capable of providing written informed consent to the study\n\nExclusion Criteria:\n\n* catether ablation procedure was unsuccessful\n* infrequent arrhythmia requiring ablation guided by pacemapping.",{"count":81,"type":21},"Outflow tract ventricular arrhythmia (OTVA) is the most common type of ventricular arrhythmia, and catheter ablation (CA) is the primary treatment option for patients experiencing symptoms. Accurately identifying the origin site of OTVA is essential for effective catheter ablation, minimizing procedural risks, and enhancing treatment success. However, most studies that developed algorithms or scoring systems for distinguishing OTVA origins excluded participants with structural heart disease and those with paced rhythms from their study groups. A recent prospective evaluation of a hybrid score (HS) that integrates both clinical and ECG data to predict OTVA-SOO, including patients with cardiac implantable electronic devices and those with structural heart disease in our study.\n\nThe presented study aimed to assess the effectiveness of the previously described hybrid algorithm in predicting OTVA-SOO in a patient population characterized by a wide basal QRS due to intraventricular conduction defects or paced rhythms.\n\nThe Hybrid Score The Hybrid Score (HS), involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.\n\nECGs were recorded with a standard configuration at a 25 mm\u002Fs sweep speed.\n\nPremature Ventricular Contraction (PVC) Ablation Activation mapping of spontaneous OTVAs was conducted. The procedure aimed to abolish spontaneous OTVAs, with the site of ablation marking the site of origin (SOO).\n\nCollected data\n\n* Patient Information and Consent (procedure must be done within 60 days of consent)\n* Demographics (age, gender, etc.)\n* Vital signs (length, weight, etc.)\n* Medical history, including cardiovascular risk factors, cardiomyopathy and drugs\n* ECG data\n* Echocardiographic data (left ventricular ejection fraction and left ventricular end-diastolic diameter)\n* Procedure data (number of radiofrequency applications, site of effective ablation, total radiofrequency time, total fluoro time, points mapping, procedure time)\n* Adverse Events",[30,110,111],"Ventricular Arrhythmias","Catheter Ablation",[113,114,115,116],"Ventricular extrasystole","Premature ventricular complex","ecg","outflow tract ventricular arrhythmias","2024-09-21",{"date":119,"type":37},"2024-09-24",{"date":121,"type":37},"2022-01-04",{"date":123,"type":21},"2024-10-23",{"name":125,"class":69},"Centro Medico Teknon",6]